[Form 4] 10x Genomics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

10x Genomics insider sale by CFO Adam Taich, the company's Chief Financial Officer and reporting person, reported a sale of 22,315 shares of Class A Common Stock on 08/22/2025 at a price of $13.787 per share. Following the sale, Mr. Taich beneficially owned 309,273 shares, reported as direct ownership. The filing explains the shares were sold to cover tax withholding obligations arising from the vesting of restricted stock units. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Taich on 08/26/2025.

Positive

• Transparent disclosure of insider sale and remaining beneficial ownership
• Sale explicitly tied to tax withholding from RSU vesting, indicating routine administrative purpose

Negative

• None.

Insights

Securities Analyst

TL;DR CFO sold a modest number of shares to cover taxes from RSU vesting; remaining ownership still material.

The sale of 22,315 Class A shares at $13.787 was disclosed as a tax-withholding disposition tied to RSU vesting, not an open-market decision to reduce exposure. Post-transaction beneficial ownership of 309,273 shares remains sizeable for an officer and is reported as direct ownership. This Form 4 provides routine transparency required under Section 16; it does not disclose any change in employment, compensation policy, or new equity grants beyond the stated tax-related sale.

Corporate Governance Expert

TL;DR Transaction appears procedural and customary for equity-based compensation tax withholding.

The explanation explicitly states the disposition was to satisfy tax withholding on vested restricted stock units, which is a common and permissible practice. The filing is properly executed by an attorney-in-fact, satisfying signature requirements. No indications of unusual timing, related-party transfers, or derivatives are present in the submission. As a governance disclosure, this Form 4 is routine and neutral in investor impact.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Taich Adam

(Last) (First) (Middle)

10X GENOMICS, INC.

6230 STONERIDGE MALL ROAD

(Street)

PLEASANTON CA 94588

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
10x Genomics, Inc. [ TXG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/22/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	08/22/2025		S(1)		22,315	D	$13.787	309,273	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units.

	/s/ Eric S. Whitaker, as Attorney-in-Fact for Adam Taich	08/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Adam Taich (TXG) report on Form 4?

He reported a sale of 22,315 Class A shares on 08/22/2025 at $13.787 per share to cover tax withholding from RSU vesting.

How many 10x Genomics (TXG) shares does the CFO own after the sale?

The filing reports beneficial ownership of 309,273 shares following the transaction, reported as direct ownership.

Why were the shares sold according to the filing?

The Explanation of Responses states the shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units.

Who signed the Form 4 for Adam Taich?

The Form 4 was signed by Eric S. Whitaker, as Attorney-in-Fact for Adam Taich, on 08/26/2025.

Does the Form 4 show any derivative transactions or new grants?

No. Table II (derivative securities) contains no reported transactions; only a non-derivative sale of Class A common stock is reported.